Global Cardiac Resynchronization Therapy Market Trends, Analysis, Growth, and Forecast: 2018 to 2027

MarketResearch.biz delivers in-depth insights on the global cardiac resynchronization therapy market in its upcoming report titled, “Global Cardiac Resynchronization Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global cardiac resynchronization therapy market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2026. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global cardiac resynchronization therapy market report has been segmented on the basis of product, end user, and region.

Request Covid - 19 Impact

Cardiac resynchronization therapy is a small device that sends electrical impulses to lower chambers of the heart, helping them to beat together in a more synchronized pattern. Implantable device helps to beat the heart more efficiently. Cardiac resynchronization therapy system consists of two components, the pulse generator, or device and thin insulted wires also known as leads. There are various benefits associated with cardiac resynchronization therapy system, as it improves the heart efficiency, increases blood flow and improves quality of life. According to research presented at the American College of Cardiology’s 63rd annual scientific session, patients with mild heart failure who uses a cardiac resynchronization therapy defibrillator device, lives longer life than those implanted with a traditional implantable cardioverter defibrillator.

Increasing incidence of cardiovascular diseases globally is expected to drive the global cardiac resynchronization therapy market over the forecast period. In addition, increasing number of product launches is expected to fuel the global cardiac resynchronization therapy market over the forecast period.  In 2017, for instance, Resonate cardiac resynchronisation therapy defibrillator (CRT-D) systems was launched by Boston Scientific in Europe. Technological innovations in cardiac resynchronization therapy is expected to boost the growth of cardiac resynchronization therapy market.

However, lack of skilled personnel and limitation of the use of cardiac resynchronization therapy in pediatric patients are major factors restraining the growth of global cardiac resynchronization therapy market over the forecast period.

North America market dominates the global cardiac resynchronization therapy market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to the increasing number of approval and subsequent launch of new product, increasing number of cases for heart failures in the region. Europe accounts for second-largest revenue share contribution to the global cardiac resynchronization therapy market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. The market in the Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years. This is attributed owing to rapidly growing geriatric population, increasing awareness and adoption for regarding cardiac resynchronization therapy devices in the region.

Global cardiac resynchronization therapy market segmentation, by product:

• CRT-Defibrillator (CRT-D)
• CRT-Pacemaker (CRT-P)

Global cardiac resynchronization therapy market segmentation, by end user:

• Hospitals
• Clinics
• Ambulatory Surgical Centres

Global cardiac resynchronization therapy market segmentation, by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Medtronic Plc.
• Jude Medical
• Boston Scientific
• Biotronik
• LivaNova Plc
• Merit Medical Systems, Inc.
• Accellent Inc.